Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences reports company developments around dermatology medical devices for in-office treatment of psoriasis, vitiligo, acne and other dermatologic conditions. Updates commonly address the XTRAC® 308 nm excimer laser, VTRAC® lamp systems, the TheraClear®X Acne Therapy System, clinical evidence for targeted UVB and photopneumatic therapies, and customer adoption by dermatology practices and academic medical centers.
Company news also covers financial results, recurring revenue and equipment sales, reimbursement and CPT coding for excimer laser treatments, international regulatory clearances such as COFEPRIS for TheraClearX in Mexico, and corporate-status events. In 2026, STRATA confirmed suspension of its common stock from The Nasdaq Capital Market and SEC filings to remove and terminate Exchange Act registration.
STRATA Skin Sciences (NASDAQ:SSKN) reported peer-reviewed results from a multicenter randomized trial in pediatric progressive vitiligo showing its 308-nm XTRAC excimer laser plus oral JAK inhibitors achieved an 85.5% overall response rate vs 53.8% with tacrolimus plus XTRAC, with only mild-to-moderate, manageable adverse events.
Face/neck response reached 97.3%, and 33 lesions achieved >95% repigmentation by week 48. STRATA is building patent protection for excimer–systemic combinations and expects AMA CPT code changes effective January 1, 2027 to triple the addressable patient population for XTRAC across inflammatory and autoimmune skin diseases.
STRATA Skin Sciences (NASDAQ: SSKN) filed a Form 25 and confirmed Nasdaq trading suspension effective February 19, 2026, and expects to file a Form 15 on or about March 2, 2026 to terminate registration and “go dark.”
The company said delisting and going dark will reduce reporting burdens and save time and money, allow management to focus on operations and growth, and noted a year-end cash balance of $8 million. The company warned shares will become more illiquid after going dark.
Johns Hopkins Dermatology added the XTRAC 308 nm excimer laser to its clinical offerings on Feb 18, 2026, expanding targeted treatment options for psoriasis, vitiligo, atopic dermatitis, and other complex inflammatory skin diseases.
The device will support patient care and ongoing clinical research at Johns Hopkins and reinforces STRATA Skin Sciences' (Nasdaq: SSKN) collaboration with leading academic centers.
STRATA Skin Sciences (NASDAQ: SSKN) highlighted a February 17, 2026 meta-analysis showing 308 nm excimer laser therapy produces substantial PASI improvements in plaque psoriasis. Reviewed trials (n sizes 20–100) reported PASI reductions of ~56%–85% with 10–14 treatments over 5–7 weeks. The analysis emphasized MED-guided dosing and session fluences typically 200–600 mJ/cm² (1–3× MED), with some protocols using higher multiples. STRATA noted its high-power XTRAC technology supports delivery of targeted high-fluence doses efficiently, enabling short treatment times and lesion-directed therapy while sparing healthy skin.
STRATA Skin Sciences (NASDAQ: SSKN) presented its XTRAC excimer laser and TheraclearX acne therapy at TeraCILAD 2025 (Nov 19-22, 2025) and reported early commercial momentum in Mexico.
The company expects more than 12 recurring TheraclearX accounts in Mexico by year-end 2025, and noted TheraclearX is now commercially available there. Speakers included Dr. Melissa Lomeli on TheraclearX clinical use and Dr. Henry Lim on XTRAC applications. STRATA highlighted clinician interest in non‑drug, device‑based acne treatments and reiterated prior XTRAC placement experience, citing potential of upwards of $30,000 annual revenue per fully developed clinic.
STRATA Skin Sciences (NASDAQ: SSKN) reported third quarter 2025 results and a corporate update on Nov 13, 2025. Q3 revenue was $6.9M, down 21% year‑over‑year; global recurring revenue was $5.5M (+3% YoY) while equipment revenue fell 60% to $1.4M. Gross profit was $4.2M (60% margin). Net loss was $1.6M, or EPS -$0.36, improving from -$0.51 in Q3 2024. Cash and equivalents were $7.1M at Sept 30, 2025.
Corporate highlights include CMS recognition of expanded CPT codes (tripling covered US patient population), COFEPRIS clearance and initial TheraClearX placements in Mexico, new peer‑reviewed publications and patents for XTRAC combination treatments, and favorable developments in litigation involving LaserOptek. U.S. XTRAC installs fell to 838; TheraClearX installs at 161.
STRATA Skin Sciences (NASDAQ: SSKN) announced that CMS finalized continued Medicare coverage and a ~3.5% payment increase for excimer laser CPT codes 96920–96922 for CY2026, and recognized an upcoming expansion of those code descriptors to include inflammatory and autoimmune conditions effective Jan 1, 2027. CMS described the excimer laser as a well-established treatment and said it will review clinical and real-world cost data during CY2027 rulemaking alongside AMA CPT revisions and RUC recommendations. STRATA reported a partner network of > 840 clinics and several hundred device owners (XTRAC and Pharos) and said it is engaging commercial payers to encourage continued excimer exclusivity beyond 2027.
STRATA Skin Sciences (NASDAQ: SSKN) will report Q3 2025 financial results on Thursday, November 13, 2025 after market close. Management will host a conference call at 4:30 p.m. ET the same day to review results and provide a corporate update, followed by a Q&A session.
U.S. callers should dial 1-866-524-3160; international callers should dial 1-412-317-6760. A live webcast will be available via the STRATA Q3 2025 Earnings Webcast. A telephonic replay will be available until November 20, 2025 using access code 3125911, and a webcast replay will remain available until May 13, 2026.
STRATA Skin Sciences (NASDAQ: SSKN) announced COFEPRIS clearance of its TheraClearX® acne treatment system under Device Registration No. 3187E2024SSA, valid through November 2029, authorizing importation, commercialization, and clinical use across Mexico.
STRATA initiated commercial rollout with partner MINO Labs, placing the first system with Dr. Melissa Lomelí Canedo in Mexico City. The company will offer TheraClearX® via its usage-based physician partnership model and plans expanded deployments, clinician training, real-world data collection, and further Latin America registrations in 2026.
Market context cited: professional acne medication segment CAGR ~10.2% to 2030, average session ~MXN 3,200 (≈USD 174), and approximately 3,000 licensed dermatologists in Mexico.
STRATA Skin Sciences (NASDAQ: SSKN) said a U.S. District Court partially granted a preliminary injunction on Nov 8, 2024, barring LaserOptek and related parties from U.S. sales/marketing that imply reimbursement under CPT codes 96920–96922 and from making false or misleading statements about STRATA products. The Court also added LaserOptek Korea as a defendant for obscuring involvement. STRATA reports >20 former Pallas buyers have switched to XTRAC, representing $1M+ in annualized capital and recurring revenue. As of June 30, 2025, STRATA’s partnership program covers 844 of ~1,200 U.S. excimer-using clinics. The AMA CPT Board reaffirmed exclusive excimer use under these codes through Jan 1, 2027, with codes broadened in May 2025 to include up to 30 conditions, potentially expanding treated patient population.